Hip Joint Prosthetic Device for Osteoarthritis, Peter Forsell Inventor

USPTO published patent application US20260108356A1 for a hip joint prosthetic device designed to treat hip joint osteoarthritis in human patients. The application, filed December 19, 2024 by inventor Peter Forsell, discloses an artificial caput femur surface adapted to contact the acetabulum surface and a fixating member stabilized by cortical bone of the collum femur. Medical device manufacturers and orthopedic companies should monitor this application for potential competitive implications in the hip replacement market.

Prosthetic Attachment System Vacuum Mechanical Suspension Patent Application

USPTO published patent application US20260108369A1 (application no. 19363285, filed 2025-10-20) for a prosthetic attachment system combining vacuum suspension and mechanical suspension. The system includes an attachment pin extending from a prosthetic liner, a connector assembly securing to a prosthetic socket, and a lanyard assembly with an external securing system. CPC classifications include A61F 2/7812 (prosthetic socket vacuum or weight-bearing chamber), A61F 2/60, A61F 2/80, and A61F 2002/7875. Five inventors are listed: Hafsteinn JONASSON, Sigurdur HANNESSON, Oskar Thor LARUSSON, Margret Sol RAGNARSDOTTIR, and Halldor ALBERTSSON.

Bunion Screw System with Offset Channel

USPTO published patent application US20260108358A1 on April 23, 2026, covering a bunion repair system with a primary bunion screw having a cannulated interior, threaded exterior, and offset channel, plus a secondary support sized for placement within the channel. Inventors: Ryan Niver, Natan Pheil, and Samuel Nader. Filing date: October 18, 2024. Application number: 18919702. CPC classifications: A61F 2/4225, A61B 17/8635, A61B 17/864, A61B 17/8886.

Interbody Device for Minimally Invasive Lumbar Fusion

USPTO published patent application US20260108362A1 titled 'Interbody Device, System, and Method, for Minimally Invasive Kambin Lumbar Lateral Interbody Fusion' on April 23, 2026. The application, filed October 6, 2025 under Application No. 19350506, covers an interbody device with a radiopaque outer body and an insertion portion whose width increases from a first end to a second end, configured for entry into a disc space during spinal fusion surgery. Inventors Anand Agarwal, Niraj Vasavada, and Darshak Shah are named on the application.

Expandable Vertebral Implant for Spinal Procedures

Two inventors, Colm McLaughlin and James Himmelberger, filed patent application 19424613 on December 18, 2025, for an expandable vertebral implant for spinal procedures. The application was published by the USPTO on April 23, 2026, disclosing a prosthetic implant with first and second members configured to coaxially interdigitate and move along a longitudinal axis.

Duchenne Muscular Dystrophy Treatment, University of Pennsylvania

The USPTO published patent application US20260109998A1 by The Trustees of the University of Pennsylvania, covering triple-splice mutants of dystrophin or utrophin, viral vectors encoding them, and compositions for treating Duchenne Muscular Dystrophy in human patients. Inventor Hansell Stedman filed the application on September 15, 2025, with CPC classifications C12N 15/86 and C07K 14/4708 indicating biotech/pharmaceutical subject matter. The application is published under Application No. 19328483.

BDNF Gene Therapy Targets Obesity, Metabolic Disorders

The USPTO has published patent application US20260109997A1 for BDNF expression constructs and vectors intended to treat metabolic disorders including obesity. The application, filed on October 11, 2023 by five named inventors including Alexandria Forbes and Matthew During, claims the disclosed gene therapy is more effective than existing BDNF-based gene therapy constructs for metabolic indications.

Juno Therapeutics Patents BCMA-Specific CARs for Immunotherapy

Juno Therapeutics, Inc. has published a patent application (US20260109774A1) for chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA) and encoding polynucleotides, published April 23, 2026. The application covers anti-BCMA antibodies, antigen-binding fragments, and genetically engineered cells expressing the CARs for use in adoptive cell therapy. The invention includes human antibodies that compete for BCMA binding with reference antibodies and is directed toward immunotherapy applications including potential cancer treatments.

Phage-Derived Particles Deliver DNA Into C. Acnes, Eligo Bioscience

USPTO published patent application US20260109991A1 by Eligo Bioscience on April 23, 2026, covering phage-derived particles for delivering DNA payloads into Cutibacterium acnes bacteria. The application, filed October 24, 2025, discloses engineered vectors with C. acnes phage packaging signals and genes of interest, along with producer cells, phage-derived particles, and methods for transducing C. acnes with transgenes. Inventors include Aymeric LEVEAU, Ines CANADAS BLASCO, Aurelie MATHIEU, and Antoine DECRULLE.

TNAP Marker Isolates Adult Multipotential Cells, Mesoblast

Mesoblast, Inc. has filed USPTO patent application US20260109783A1 (Application No. 19080304), published April 23, 2026, covering the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and isolating adult multipotential cells. The application names Stan Gronthos, Andrew Christopher William Zannettino, and Paul John Simmons as inventors and discloses cell populations enriched by the disclosed methods along with therapeutic uses of these cells. The filing date was March 14, 2025.

CRISPR-Cas Type I-F3 Transposon Systems for DNA Integration Patent Application

USPTO published patent application US20260110001A1 disclosing recombinant Type I-F3 transposon-associated CRISPR-Cas systems and methods for DNA integration. The application, filed June 7, 2023 by inventors Rodolphe Barrangou and Avery Roberts under application number 18872321, covers CRISPR-Cas nucleic acid constructs combined with Tn7-like transposon systems. This publication makes the invention publicly available for examination and potential licensing or competing development.

University of California Files Tumor-Neoantigen Antibody Patents for Cancer

The Regents of the University of California filed patent application US20260109786A1 on April 23, 2026, covering chemically controlled monoclonal antibodies reactive with tumor-specific neoantigens and neoantigen-binding fragments. The application also discloses related nucleic acids, expression cassettes, and expression vectors encoding the antibodies. Inventors include Charles S. CRAIK, Kevan M. SHOKAT, Ziyang ZHANG, and Peter J. ROHWEDER. The antibodies and fragments are disclosed as useful for cancer diagnosis and treatment.

Merck Stable PD-1 Antibody Formulations 5-250 mg/mL Pembrolizumab Cancer Treatment

Merck Sharp & Dohme LLC filed USPTO Application US20260109768A1 on April 23, 2026, covering stable formulations of anti-PD-1 antibodies (5-250 mg/mL concentration range) with buffer, stabilizer, surfactant, and antioxidant excipients, specifically identifying pembrolizumab as the target antibody. The application names William P. Forrest Jr., Chakravarthy Nachu Narasimhan, and Yogita Krishnamachari as inventors and claims methods for treating various cancers via intravenous or subcutaneous administration. Patent prosecution will determine scope and grant likelihood.

MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR SOLID TUMORS

Amgen Inc. filed patent application US20260109776A1 covering human agonistic CD40 multispecific antibody constructs engineered to target the CD40 pathway on tumor-associated APCs for the treatment of solid tumors without systemic CD40 activation. The application was published on April 23, 2026 with filing date December 16, 2025 and application number 19421479, naming six inventors including Xin Yu, Jackson Egen, Fernando Garces, Shunsuke Takenaka, AeRyon Kim, and Deepali Sawant. CPC classifications span C07K 16 antibody constructs and A61P 35/04 for antineoplastic agents.

Anti-PiLRA Antibodies, Uses Thereof, and Related Methods and Reagents

Denali Therapeutics Inc. filed patent application 18714069 on December 16, 2022, published as US20260109763A1 on April 23, 2026, covering anti-PILRA antibodies with selectivity profiles allowing comparable binding to cynomolgus and human PILRA proteins while exhibiting much weaker binding to human PILRB protein. The antibodies bind both PILRA G78 and R78 variants and may be used in animal studies without surrogate molecules and for treating subjects with either PILRA variant. This is a standard USPTO patent application publication and does not create compliance obligations.

Monovalent CD47 Binding Proteins - Caedo Oncology, Apr 23, 2026

Caedo Oncology AS has published patent application US20260109764A1 for monovalent CD47 binding proteins and antibodies for therapeutic use. The application, filed October 9, 2023, claims binding proteins with one antigen binding domain targeting specific amino acid residues (Q19, N45, T120, R121, E122, G123) within CD47 as defined by SEQ ID NO:19. The inventors are Kjetil Hestdal, Rolf Dagfinn Pettersen, Nina Richartz, Sittana Matar, and Seham Skah. This publication makes the application available for public inspection and potential prior art challenges.

Formulations With Reduced Degradation of Polysorbate, Genentech

USPTO published patent application US20260108611A1 assigned to Genentech, Inc. on April 23, 2026, with a filing date of December 18, 2025. The application covers aqueous pharmaceutical formulations comprising a polypeptide, polysorbate, and cyclodextrin designed to reduce polysorbate degradation and decrease visible and sub-visible particle formation. Inventors are Brian ConnOLLY, Lydia Hamburg, and Emily Holz.

Selective Targeting of Host CD70+ Alloreactive Cells to Prolong Allogeneic CAR T Cell Persistence

Allogene Therapeutics, Inc. filed USPTO Patent Application US20260109771A1, published April 23, 2026, covering CD70-binding proteins, engineered immune cells (CAR-T cells), and methods for treating cancer including solid tumors and hematologic tumors. The application also claims engineered cells expressing both a CD70 CAR and a second CAR targeting a cancer-characteristic molecule, with optional reduction of TRAC, CD52, or CD70 expression. The filing date was December 15, 2025.

Chugai Seiyaku Bispecific Antibody Substitutes Coagulation Factor VIII

Chugai Seiyaku Kabushiki Kaisha filed patent application US20260109782A1 for bispecific antibodies that specifically bind to both Factor IX/Factor IXa and Factor X, functionally substituting for blood coagulation Factor VIIIa. The disclosed antibody A44/B26 reduced coagulation time by 50 seconds or more compared to untreated controls. The inventors further developed commonly shared light-chain antibodies using the L chain from antibody A44, demonstrating that A44L can serve as shared L chains for multispecific antibody constructs with appropriate CDR shuffling.

Harpoon Therapeutics Trispecific Protein BCMA Patent Application

Harpoon Therapeutics, Inc. filed patent application US20260109773A1 covering B cell maturation agent (BCMA) targeting trispecific proteins. The disclosed proteins comprise a CD3 binding domain, a half-life extension domain, and a BCMA binding domain, along with pharmaceutical compositions, nucleic acids, and methods of use for treating diseases and disorders. Application No. 19249844 was filed June 25, 2025, with inventors Holger Wesche, Bryan D. Lemon, and Richard J. Austin listed.

Anti-HER2 Antibodies and Methods of Use Thereof

The USPTO published patent application US20260109781A1 for anti-HER2 antibodies on April 23, 2026, filed October 8, 2025 under application number 19352786. The application covers antibodies binding to subdomain II and/or subdomain IV of human HER2, including bispecific formats using a common light chain, for treating cancer and brain metastasis. Inventors include Abira Bandyopadhyay, Allisa Jayne Clemens, Do Jin Kim, Michelle E. Pizzo, Lu Shan, Richard Théolis Jr., and Raymond Ka Hang Tong.

Anti-IL6 Receptor Antibody Treats Rheumatoid Arthritis

USPTO published patent application US20260108601A1 on April 23, 2026, filed September 22, 2025, covering methods of treating rheumatoid arthritis using an anti-IL6 receptor antibody in subjects with specific serum biomarker concentrations. The application names Anita Boyapati, Jérôme Msihid, and Moshe E. Zilberstein as inventors. Pharmaceutical and biotechnology companies developing IL-6 targeted therapies for autoimmune conditions may wish to monitor this application's prosecution for potential freedom-to-operate considerations.

University of Chicago Bacteriophage Patent for Bacterial Infections

The University of Chicago has received a published patent application (US20260108570A1) for bacteriophage compositions and methods targeting Enterobacteriaceae infections, including Klebsiella. The application, filed August 1, 2023, covers isolated bacteriophage sequences with at least 99% identity to SEQ ID NO:1-74, along with associated devices, kits, and treatment methods. Inventors include Mark MIMEE and Ella ROTMAN.

Mycobacteriophage Compositions and Related Methods, Oregon State University

USPTO published patent application US20260108571A1 for Oregon State University on April 23, 2026, covering isolated bacteriophages with lytic activity against mycobacterial species, including the specific phage Pill582 and variants thereof. The application (filed 2025-10-20, Application No. 19363116) discloses phage cocktails, pharmaceutical compositions, and methods for treating mycobacterial infections and associated disease conditions.

Probiotic Preparation Containing Akkermansia Muciniphila Akk11 Strain for Alleviating Hypertension

USPTO published patent application US20260108565A1 on April 23, 2026, covering a probiotic preparation combining Akkermansia muciniphila Akk11 strain with Lactobacillus rhamnosus LRa05 strain for alleviating hypertension. The application, originally filed July 9, 2024 under application number 18879015, names Shuguang Fang, Yao Dong, Yunjiao Zhao, Zhonghui Gai, and Jianguo Zhu as inventors. The CPC classifications include A61K 35/741, A61P 9/12, and A61K 2035/115, indicating pharmaceutical preparations containing probiotics and anti-hypertensive agents.

Engineered Immune Effector Cell with CD16 Protein for Shear Resistance

USPTO published patent application US20260108605A1, filed September 27, 2023, covering a genetically modified immune effector cell expressing a recombinant human CD16 protein engineered with amino acid additions, deletions, and replacements that confer enhanced shear resistance. The application names five inventors: Fuwei JIANG, Tingting LIU, Yifang WANG, Cuiqing YANG, and Zhuoxiao CAO. CPC classifications span immunology (A61K 38/1774, A61K 39/39558), oncology (A61P 35/00), and protein engineering (C07K 14/7051, C07K 16/2803).

Anti-Cancer Therapy Methods Using Autophagy Induction via DBI Inhibition

USPTO published patent application US20260108602A1 covering methods and systems for improving anti-cancer therapies through autophagy induction via inhibition of extracellular diazepam binding inhibitor (DBI). Inventors include Mark de Boer, Guido Kroemer, Léa Montegut, Isabelle Martins, Hui Pan, Hui Chen, and Sijing Li, with application number 19361314 filed October 17, 2025. The application claims therapeutic compositions, methods, and regimens for cancer treatment, including chemo- and immunotherapies.

US20260108572A1 - Alzheimer's Dementia Suppressant Using Sesamum Indicum Extract

USPTO published patent application US20260108572A1, filed September 1, 2023 and made publicly available on April 23, 2026, disclosing an Alzheimer-type dementia suppressant composition and method of manufacture using an aboveground part of Sesamum indicum (sesame plant) or an extract thereof as the active ingredient. The application names Sakamoto Yakusouen, LLC as assignee and Johji YAMAHARA as inventor. CPC classifications include A61K 36/185, A61K 31/7048, A61P 25/28, and related formulation codes A61K 2236/17, A61K 2236/333, A61K 2236/51, and A61K 2236/53. The application does not yet represent an issued patent and carries no compliance obligation.

Methods of Treating Fibromyalgia With Psilocybin Compositions - Tryp Therapeutics

Tryp Therapeutics Inc. filed patent application US20260108545A1 with the USPTO on September 11, 2023 (application no. 19110772), published April 23, 2026. The application covers methods for treating fibromyalgia using psychedelics such as psilocybin or metabolites thereof, optionally combined with psychotherapy, with patient outcomes assessed through observer-rated and subject-reported measures as well as biological and clinical indicators. The inventors are James GILLIGAN and Peter GUZZO. Pharmaceutical and biotech companies pursuing psychedelic-based therapeutic research should monitor this filing as it may affect competitive patent positioning in fibromyalgia treatment.

FGF21 GLP1 Double Gene-Modified Mesenchymal Stem Cell Patent Application for Metabolic Disease Treatment

The USPTO published patent application US20260108558A1, filed August 21, 2025, covering a modified mesenchymal stem cell engineered to co-express FGF21 and GLP-1 proteins, intended for treating metabolic diseases. The application names inventors Haifeng DUAN, Binghua XUE, Jing XIE, and Zhenli ZHANG, and specifies CPC classifications including A61K 35/28, A61P 3/10, C07K 14/50, C07K 14/605, and various C12N cellular-therapy classifications. Publication of this application creates prior art that may affect freedom-to-operate analyses for parties developing related cellular-therapy approaches for metabolic disease.

EGFR Inhibitors for Treatment-Resistant Non-Small Cell Lung Cancer

USPTO has published patent application US20260108524A1 for methods of treating treatment-resistant non-small cell lung cancer using EGFR inhibitors. The application, filed October 16, 2023, names David A. Nathanson, Jonathan Tsang, and Timothy F. Cloughesy as inventors. CPC classifications include A61K 31/519, A61K 31/517, and A61P 35/00. This publication represents new intellectual property activity in the targeted oncology space.

Bifidobacterium Longum Subsp. Infantis BI03 Strain for Alleviating Parkinson's Disease

The USPTO has published application US20260108568A1 for a Bifidobacterium longum subsp. infantis BI03 strain (CGMCC No. 24473, deposited March 7, 2022) for alleviating Parkinson's disease. The application claims the strain can alleviate Parkinson's-related dyskinesia and corticosterone elevation, weaken associated neuroinflammation, promote glutathione, and reduce brain oxidative stress damage. Inventors include Shuguang FANG, Yao DONG, Yixuan FAN, Zhonghui GAI, and Jianguo ZHU; the application was filed May 27, 2024.

Bispecific CARs Targeting CD20 BCMA, AbelZeta, Autoimmune, Cancer

AbelZeta Inc. filed US Patent Application US20260108557A1 for a bispecific chimeric antigen receptor (CAR) targeting both CD20 and BCMA antigens simultaneously. The CAR construct comprises an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The application was filed on October 13, 2025, and published on April 23, 2026, with claims directed to methods of treating autoimmune disorders and cancer using the disclosed CAR.

Longitudinal Study of Debt Advice, £1,767,867

The Money and Pensions Service has modified contract C0668 for the Longitudinal Study of Debt Advice, increasing the total contract value from £1,250,000 to £1,767,867. The study, awarded to IFF Research Ltd in April 2024, runs for 64 months and is conducted in Bedfordshire and Hertfordshire (UKH2). The research uses a randomised encouragement design across four waves to measure the causal impact of debt advice on financial wellbeing outcomes over short, medium, and long terms.

Bristol City Council £6M Cashless Parking Market Engagement Notice

Bristol City Council has issued a preliminary market engagement notice for cashless telephone parking services covering the City of Bristol, with an estimated contract value of £6,000,000 including VAT over a five-year term (December 2026 to November 2031) extendable to ten years. The council is hosting a virtual supplier information event on 11 May 2026 from 1:30–2:30pm via MS Teams to brief prospective bidders on requirements and procurement approach ahead of formal ITT publication estimated for 18 May 2026. Interested contractors must register by emailing penny.sharp@bristol.gov.uk.

Repair, Maintenance and Servicing of Laundry Equipment, £90k, 7th May

The Ministry of Defence has published a below-threshold open competition tender for the repair, maintenance and servicing of laundry equipment over a three-year period from 14 May 2026 to 31 March 2029. The estimated contract value is £75,000 excluding VAT (£90,000 including VAT). Tender submissions are due by 7 May 2026 at 10:00am via the electronic submission address at contracts.mod.uk, with the Most Advantageous Tender evaluation criteria applying to contract award.

Hackney Parent Carer Forum Hosting Contract, £47,897, Deadline 20 May 2026

The London Borough of Hackney has published a tender notice seeking a provider to host a Parent Carer Forum for Special Educational Needs and Disability (SEND) services. The contract is valued at £47,897 including VAT, running from 1 August 2026 to 31 July 2027 with an optional 12-month extension. The procurement is open to SMEs and VCSEs, with quality weighted at 80% and price at 20% of the award criteria. Tenders must be submitted electronically by 20 May 2026 at 12:00pm.

Thanet District Council Backup Solution Platform Procurement

Thanet District Council has published a tender notice for a replacement backup solution platform covering all council data held on premises and in its Google environment. The estimated contract value is £288,000 including VAT, with a five-year term from July 2026 to July 2031. Suppliers must submit completed tender documents via the Kent Business Portal by 12:00pm on 18 May 2026, with clarifications due by 7 May 2026. Evaluation will be weighted 60% on quality and 40% on price.

Halton Place Care at the Chemist £39k Pharmacy Contract Award

NHS Cheshire and Merseyside Integrated Care Board awarded a £39,000 contract via Direct Award A to selected Halton pharmacies for the Care at the Chemist (CATC) minor ailment service. The one-year contract commenced 1 April 2026 and expires 31 March 2027. The contract was awarded under the Provider Selection Regime (PSR) confirming that Public Contracts Regulations 2015 do not apply to this procurement.

Birmingham City Council Awards £180k Pest Control Contract to JMS BFD Limited

Birmingham City Council has awarded a £180,000 contract for pest control products and application equipment to JMS BFD Limited (trading as Copley Pest Solutions Ltd). The three-year contract runs from 11 May 2026 to 10 May 2029. The procurement was conducted as a below-threshold open competition exercise under the Procurement Act 2023.

University of Chester Seeks Fire Safety Maintenance Services, Deadline April 30

The University of Chester has published a preliminary market engagement notice under the Procurement Act 2023 for forthcoming fire safety equipment maintenance services. The university plans to tender via open procedure for statutory compliance and planned preventative maintenance on fire safety equipment, with an estimated contract period from August 1, 2026 to July 31, 2029, potentially extendable to July 31, 2031. Engagement deadline is April 30, 2026, and the tender notice is estimated to publish on the same date. The opportunity is open to SMEs and VCSE organisations.

Derbyshire Police High Risk Offender PRS Accommodation Sourcing Trial

The Police and Crime Commissioner for Derbyshire has issued a Preliminary Market Engagement (PME) notice under the Procurement Act 2023 to gather market information from providers capable of sourcing private rented sector tenancies for high-risk offenders. The proposed pilot (reference DP1085-01) would run from 1 June 2026 to 31 May 2027 and targets SMEs and voluntary, community and social enterprises. Providers must respond via the UK e-Procurement Portal by 8 May 2026, with the formal tender notice estimated for publication on 22 May 2026. The engagement covers accommodation services classified under social work services with accommodation and related property management CPV codes.

Forestry England Security Services, £504k, deadline 15th May

Forestry England, operating under the Forestry Commission, has published a preliminary market engagement notice under the Procurement Act 2023 seeking expressions of interest for a Security Service contract across multiple sites in England. The contract is structured into four geographical lots (East, West, South, Central) spanning all of England, with an estimated total value of £504,000 including VAT over a five-year term from 1 September 2026 to 31 August 2031. The engagement deadline is 15 May 2026; however, the notice explicitly states it does not commit Forestry England to any future procurement.

British Embassy Baghdad Internet Contract £311k to Supercell

The Foreign, Commonwealth and Development Office (FCDO) has awarded a contract for internet infrastructure and associated services at the British Embassy in Baghdad to Supercell Network for Internet Services Ltd. The contract has an initial one-year value of £143,264, with options to extend for up to two additional years bringing the total potential value to £311,336 excluding VAT. Hardware costs are capped at £50,000 and the contract covers high-availability internet connectivity, hardware supply, configuration, testing, deployment, and ongoing support.

13 Pounder Design Organisation, £3M, deadline 29th May

Defence Equipment and Support (DE&S) has published a tender notice for a Design Organisation (DO) to provide through-life design authority, engineering assurance, configuration management, and technical documentation support for the Ordnance Quick Fire 13-Pounder ceremonial guns operated by The King's Troop Royal Horse Artillery. The estimated contract value is £2,500,000 excluding VAT (£3,000,000 including VAT), with an initial performance period from 13 October 2026 to 15 October 2029, extendable to 8 October 2030. Bids must be submitted electronically via the MOD contracts portal by 29 May 2026 at 11:59pm.

Xie v. United States Department of State et al

Zefan Xie filed a civil complaint in the Northern District of California on April 23, 2026, naming as defendants the United States Department of State, Secretary of State Marco Rubio, the U.S. Consulate General in Guangzhou, China, and Pauline Kao. The case is classified under 'Other Immigration Actions' nature of suit. The complaint seeks judicial review of consular or departmental actions affecting the plaintiff's immigration status or benefits.

WH Smith H1 Revenue Up 5% to £748m

WH Smith PLC released H1 FY2026 interim results for the period ended 28 February 2026, reporting total Group revenue of £748m, a 5% increase year-over-year (2025: £716m). The Board has suspended the dividend to reduce debt and strengthen the Group's financial position, with FY26 headline profit before tax expected in the range of £90m-£105m. By division, UK revenue was £392m (+2%), North America £204m (+5% or +10% constant currency), and Rest of World £152m (+10% or +8% constant currency).

RWS Holdings H1 Trading Statement, £360m Revenue

RWS Holdings plc, a global AI solutions company listed on AIM (RWS.L), reports first half revenue of approximately £360m for the six months ended 31 March 2026, representing approximately 5% growth on the prior year. Organic constant currency revenue grew by approximately 7%, with the Generate segment delivering strong double-digit growth driven by the TrainAI business unit, while the Transform segment declined as the company pivots to technology-first solutions. Adjusted profit before tax is expected to be approximately £24m, up from £18m in H1 FY25, with net debt of approximately £33m as of 31 March 2026. The company confirms full-year performance is expected to be in line with market guidance.

RELX AGM Trading Update, Strong Growth Outlook

RELX PLC has issued its AGM trading update for April 2026, reporting strong underlying revenue and profit growth across all four business areas (Risk, Scientific Technical & Medical, Legal, and Exhibitions) in the first quarter. The company reaffirms its full-year outlook, expecting strong underlying growth in revenue and adjusted operating profit, as well as strong growth in adjusted earnings per share on a constant currency basis. The update highlights continued shift in business mix toward higher-growth AI-enabled analytics and decision tools driving the improving long-term growth trajectory.

SEGRO Q1 2026 Trading Update: £23M New Rent, £73M Development Pipeline, £106M Disposals

SEGRO plc reports £23 million of new headline rent contracted in Q1 2026 (January–March), comprising £11 million from the existing portfolio and £12 million of development lettings. Customer retention stood at 83 percent and occupancy at 94.8 percent, with development completions of 40,000 sq m generating £4 million of headline rent. Development projects under construction or in advanced negotiations represent £73 million of potential rent at a 7.6 percent development yield. The group completed £106 million of disposals above book value with a further £138 million exchanged and due to complete later in 2026.